
AB Science S.A (AB) | Financial Analysis & Statements
AB Science S.A. | Small-cap | Healthcare
AB Science S.A. | Small-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
23.2M
Total Liabilities
46.9M
Shareholders Equity
-23.8M
Cash Flow Metrics
Revenue & Profitability Trend
AB Science S.A Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 1.1M | 970.0K | 958.0K | 1.6M | 1.6M |
Cost of Goods Sold | -176.0K | 383.0K | 31.0K | 111.0K | 69.0K |
Gross Profit | 1.2M | 587.0K | 927.0K | 1.5M | 1.5M |
Gross Margin % | 116.4% | 60.5% | 96.8% | 93.1% | 95.6% |
Operating Expenses | |||||
Research & Development | 3.9M | 10.5M | 13.3M | 11.2M | 12.8M |
Selling, General & Administrative | 1.9M | 1.8M | 2.2M | 2.7M | 3.4M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 5.9M | 12.3M | 15.5M | 14.0M | 16.3M |
Operating Income | -6.1M | -13.4M | -15.9M | -13.8M | -14.7M |
Operating Margin % | -567.4% | -1,384.4% | -1,663.7% | -859.2% | -931.7% |
Non-Operating Items | |||||
Interest Income | 0 | 2.7M | 1.1M | 887.0K | 63.0K |
Interest Expense | 2.2M | 2.5M | 2.0M | 1.3M | 117.0K |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -7.8M | -12.0M | -13.6M | -14.4M | -15.0M |
Income Tax | - | 0 | 4.0K | 36.0K | 8.0K |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -7.8M | -12.0M | -13.6M | -14.5M | -15.0M |
Net Margin % | -730.5% | -1,235.6% | -1,421.2% | -900.0% | -950.4% |
Key Metrics | |||||
EBITDA | -5.1M | -7.4M | -11.6M | -11.4M | -13.8M |
EPS (Basic) | €-0.15 | €-0.24 | €-0.29 | €-0.30 | €-0.34 |
EPS (Diluted) | €-0.15 | €-0.24 | €-0.29 | €-0.30 | €-0.34 |
Basic Shares Outstanding | 53274886 | 49664905 | 47139023 | 47520850 | 44225682 |
Diluted Shares Outstanding | 53274886 | 49664905 | 47139023 | 47520850 | 44225682 |
Income Statement Trend
AB Science S.A Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 8.0M | 6.1M | 7.3M | 8.7M | 20.7M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 130.0K | 236.0K | 160.0K | 310.0K | 354.0K |
Inventory | 184.0K | 336.0K | 456.0K | 141.0K | 79.0K |
Other Current Assets | - | - | - | - | - |
Total Current Assets | 14.5M | 19.4M | 20.9M | 18.2M | 26.3M |
Non-Current Assets | |||||
Property, Plant & Equipment | 256.0K | 254.0K | 1.2M | 1.5M | 2.4M |
Goodwill | 1.3M | 1.4M | 1.6M | 1.4M | 1.5M |
Intangible Assets | 1.3M | 1.4M | 1.6M | 1.4M | 1.5M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | - | 3.0K | 3.0K | 3.0K | 2.0K |
Total Non-Current Assets | 8.7M | 6.1M | 3.0M | 3.1M | 3.4M |
Total Assets | 23.2M | 25.5M | 23.8M | 21.3M | 29.7M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 6.0M | 6.5M | 7.4M | 6.3M | 13.3M |
Short-term Debt | 3.9M | 2.1M | 4.7M | 629.0K | 4.7M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 1.9M | 303.0K | 841.0K | 43.0K | 33.0K |
Total Current Liabilities | 20.4M | 18.7M | 23.1M | 17.5M | 22.6M |
Non-Current Liabilities | |||||
Long-term Debt | 14.5M | 17.0M | 19.3M | 7.7M | 2.3M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 11.1M | 9.9M | 11.8M | 11.5M | 10.2M |
Total Non-Current Liabilities | 26.5M | 27.8M | 36.4M | 27.0M | 26.6M |
Total Liabilities | 46.9M | 46.5M | 59.5M | 44.5M | 49.2M |
Equity | |||||
Common Stock | 579.0K | 511.0K | 469.0K | 469.0K | 459.0K |
Retained Earnings | - | - | - | - | - |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | -23.8M | -21.0M | -35.7M | -23.2M | -19.5M |
Key Metrics | |||||
Total Debt | 18.5M | 19.1M | 24.0M | 8.4M | 7.1M |
Working Capital | -5.9M | 707.0K | -2.2M | 705.0K | 3.7M |
Balance Sheet Composition
AB Science S.A Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -7.8M | -12.0M | -13.6M | -14.5M | -15.0M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 1.0M | 605.0K | 133.0K | 258.0K | 95.0K |
Working Capital Changes | 0 | 0 | 0 | 0 | 0 |
Operating Cash Flow | -6.2M | -14.7M | -14.6M | -13.4M | -14.8M |
Investing Activities | |||||
Capital Expenditures | -136.0K | -345.0K | -644.0K | -564.0K | -370.0K |
Acquisitions | - | - | - | - | - |
Investment Purchases | 0 | 0 | 0 | 0 | 0 |
Investment Sales | 0 | 0 | 0 | 0 | 0 |
Investing Cash Flow | -136.0K | -345.0K | -644.0K | -564.0K | -370.0K |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 0 | 6.0M | 16.6M | 6.0M | 6.1M |
Debt Repayment | -2.4M | -1.2M | -188.0K | -4.3M | -6.0K |
Financing Cash Flow | -2.4M | 4.8M | 16.4M | 1.7M | 6.1M |
Free Cash Flow | 370.0K | -17.2M | -18.1M | -17.7M | -13.9M |
Net Change in Cash | -8.7M | -10.3M | 1.2M | -12.3M | -9.2M |
Cash Flow Trend
AB Science S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-8.93
Forward P/E
-6.14
Price to Sales
78.81
PEG Ratio
-6.14
Profitability Ratios
Profit Margin
116.42%
Operating Margin
-488.48%
Return on Equity
32.97%
Return on Assets
-15.62%
Financial Health
Current Ratio
0.71
Debt to Equity
-0.78
Beta
1.59
Per Share Data
EPS (TTM)
€-0.15
Book Value per Share
€-0.37
Revenue per Share
€0.02
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
ab | 84.5M | -8.93 | - | 32.97% | 116.42% | -0.78 |
Ipsen S.A | 8.9B | 19.70 | 2.07 | 10.89% | 11.91% | 22.74 |
Vetoquinol S.A | 895.6M | 15.24 | 1.55 | 10.64% | 10.88% | 3.67 |
CoreTech Limited | 3.1M | - | - | -102.42% | 137.36% | -0.95 |
Boiron S.A | 368.1M | 32.62 | 0.97 | 2.95% | 2.33% | 3.96 |
Euroapi S.A.S.U | 276.1M | 8.84 | 0.28 | -13.49% | -14.08% | 7.17 |
Financial data is updated regularly. All figures are in the company's reporting currency.